Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CERo Therapeutics Holdings Inc (CEROW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/13/2025: CEROW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.33% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/13/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.43 | 52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 |
52 Weeks Range 0.00 - 0.04 | Updated Date 06/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -122.86% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 317536 |
Shares Outstanding - | Shares Floating 317536 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
CERo Therapeutics Holdings Inc
Company Overview
History and Background
CERo Therapeutics Holdings Inc. is a biotechnology company focused on the development and commercialization of innovative cancer immunotherapies. The company's origins and founding year are currently difficult to ascertain based on publicly available information.
Core Business Areas
- Immuno-oncology: Developing novel immunotherapies targeting cancer cells and modulating the immune system.
Leadership and Structure
Details regarding the specific leadership team and organizational structure of CERo Therapeutics Holdings Inc. are not easily available in a structured format publicly.
Top Products and Market Share
Key Offerings
- Novel Immunotherapies: CERo Therapeutics is focused on novel immunotherapies, but specific product names, market share, number of users, or revenue figures are not currently available in a structured format. Competitors in this space include larger pharmaceutical and biotech companies developing checkpoint inhibitors, cell therapies, and other immunotherapeutic modalities. Such companies include PFE (Pfizer), MRK (Merck), and BMY (Bristol Myers Squibb)
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing rapid growth, driven by increasing cancer incidence and advancements in understanding the immune system's role in fighting cancer.
Positioning
Without detailed information, it is difficult to ascertain CERo Therapeutics' precise positioning. Generally speaking, many small biotech companies are developing technology platforms with the intent of being acquired.
Total Addressable Market (TAM)
The global immuno-oncology market is expected to reach hundreds of billions of dollars in the coming years. CERo Therapeutics Holdings Inc.'s positioning relative to this TAM depends on the success of its pipeline.
Upturn SWOT Analysis
Strengths
- Focus on innovative immuno-oncology therapies
- Potential for breakthrough cancer treatments
- Proprietary Technology Platforms
Weaknesses
- Early stage of development
- Limited financial resources
- High regulatory hurdles
- Information Scarcity
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new cancer indications
- Breakthrough therapy designations
- Acquisition from a larger company
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory setbacks
- Funding challenges
Competitors and Market Share
Key Competitors
- PFE
- MRK
- BMY
Competitive Landscape
CERo Therapeutics is a very small player compared to pharmaceutical giants. Advantages could be its early-stage technology; disadvantages are its resource constraints.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable.
Future Projections: Future projections are difficult to determine due to limited information.
Recent Initiatives: Information on recent strategic initiatives is limited in public sources.
Summary
CERo Therapeutics Holdings Inc. is a development stage biotechnology company pursuing novel cancer immunotherapies. Limited information is available regarding its specific pipeline, financial performance, and competitive positioning. Its success depends on the advancement of its technology, securing funding, and navigating regulatory hurdles. The immuno-oncology market presents significant opportunities, but the company faces strong competition from established players.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website (if available)
- Market Research Reports (Limited Access)
- Public News Sources
Disclaimers:
The data provided is based on publicly available information and may be incomplete or inaccurate. This analysis is for informational purposes only and should not be considered financial advice. The market share data is estimates based on general market trends.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CERo Therapeutics Holdings Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-11-29 | CEO & Chair Mr. Christopher B. Ehrlich M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.cero.bio |
Full time employees 8 | Website https://www.cero.bio | ||
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.